Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model
Keywords: lithium; valproic acid; GSK-3β; ALS; G93A mice; behavioral deficitsALS, amyotrophic lateral sclerosis; Bcl-2, beta cell lymphoma-2; GSK-3, glycogen synthase kinase-3; HDAC, histone deacetylase; PBS, phosphate-buffered saline; SOD1, superoxide dismutase-1;